With a 60% Gross margin and tightly held other costs the impact on NPAT of this type of sales increase is quite large.
On my back of the ennelope analysis a sales increase in FY'25 to $16m whilst maintaining GM% should result in a break even NPAT.
Any sales surge above $4m per quarter will likely see Biome deliver its maiden NPAT.
Cheers......D
Ann: Q1 FY25 Revenue Guidance, page-12
-
- There are more pages in this discussion • 7 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add BIO (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
72.0¢ |
Change
0.090(14.3%) |
Mkt cap ! $155.0M | |||
| Open | High | Low | Value | Volume |
| 67.5¢ | 74.5¢ | 64.0¢ | $2.082M | 3.002M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 51963 | 72.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 74.0¢ | 25000 | 1 |
View Market Depth
| Last trade - 16.10pm 03/09/2024 (20 minute delay) ? |
| BIO (ASX) Chart |